---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056912"
form_type: "8-K"
ticker: null
cik: "0001828522"
company_name: "eFFECTOR Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:55:43.563753+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# eFFECTOR Therapeutics enters $50M ATM equity facility with H.C. Wainwright; terminates prior Cantor agreement

## Summary
- New ATM offering agreement allows sale of up to $50M in common stock via H.C. Wainwright; agent commission 3.0%.
- Prior ATM agreement with Cantor Fitzgerald terminated; company had sold 1.075M shares for $9.8M under that program.
- Sales under new agreement are at-the-market on Nasdaq; no obligation to sell any shares.

## SEC filing metadata
- accession: 0000950170-24-056912
- form_type: 8-K
- cik: 0001828522
- company_name: eFFECTOR Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828522/000095017024056912/0000950170-24-056912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828522/000095017024056912/eftr-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056912
- JSON: https://secwatch.observer/filing/0000950170-24-056912.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056912.txt

## Key facts
- Material Agreements
  eFFECTOR Therapeutics, Inc. terminated Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (effective 2024-05-09).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Effective: 2024-05-09
  source text: On May 9, 2024, the Company terminated its Controlled Equity Offering SM Sales Agreement, dated September 1, 2022, with Cantor Fitzgerald & Co. (the “Prior Sales Agreement”), pursuant to which the Company was able sell shares of common stock in “at the market offerings” as defined by Rule 415 of the Securities Act.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000095017024056912/0000950170-24-056912-index.htm
- Material Agreements
  eFFECTOR Therapeutics, Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $50.0 million (effective 2024-05-09).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: up to $50.0 million
  - Effective: 2024-05-09
  source text: On May 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock having an aggregate offering price of up to $50.0 million through the Agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000095017024056912/0000950170-24-056912-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.